The record
In 2019 FDA issued escalating safety alerts and four voluntary recalls occurred: Claire's products (alert March 5, 2019, positive for tremolite asbestos), Beauty Plus Global and Claire's JoJo Siwa Makeup Set (recalls May 29-30, 2019), four additional Beauty Plus Global 'City Color' products (recall September 6, 2019), and Johnson's Baby Powder lot 22318RB (recall October 18, 2019).
Claim scope
The 2019 enforcement chronology with dates, products, lots and SKUs, from FDA's own alert. Fiber type is specified as tremolite for the March 2019 Claire's products. Testing for the Claire's action 'was conducted on behalf of FDA by the Occupational Safety and Health Administration and AMA Analytical Services, Inc.' FDA noted at the time: 'Claire's has informed us that it does not believe that affected products are still available for sale' and 'The FDA is not aware of any adverse reactions associated with exposure to these Claire's products.'
What this source does not establish
These are VOLUNTARY recalls of SPECIFIC LOTS in 2019 — not findings that Claire's, Beauty Plus Global, or Johnson & Johnson sell contaminated product today. HARD RULE: the page must date-stamp every one of these ('tested positive in 2019', never 'is contaminated'). Does NOT establish FDA mandated the recalls; FDA lacked mandatory cosmetic recall authority at the time.
Limitations
Note the March 2019 Claire's alert lists an 'Eye Shadows' lot 08/17 that does not appear as a positive in the FY19 AMA summary table; the FY19 table's Claire's positives are Compact Powder lot 06/16 and Contour Palette lot 04/17 plus the TEM-only JoJo Siwa set. The eye shadow positive traces to the separate OSHA analysis (sample 761227), not the AMA table — cite the OSHA report for it, not the AMA table.
Source
Gov Report — FDA Safety Alert, 'FDA Advises Consumers to Stop Using Certain Cosmetic Products' (updated through Oct. 18, 2019; page content current as of 02/25/2022); FDA Constituent Update June 6, 2019, 'FDA Alerts Consumers About Cosmetic Products Recalled due to the Presence of Asbestos'; FDA Constituent Update Oct. 18, 2019